MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

We analysed the prognostic significance of minimal residual disease (MRD) level in adult patients with acute myeloid leukemia (AML) treated in the randomized gemtuzumab ozogamicin (GO) ALFA-0701 trial. Levels of WT1 and NPM1 gene transcripts were assessed using cDNA-based real-time quantitative PCR...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Lambert, Juliette, Lambert, Jérôme, Nibourel, Olivier, Pautas, Cécile, Hayette, Sandrine, Cayuela, Jean-Michel, Terré, Christine, Rousselot, Philippe, Dombret, Hervé, Chevret, Sylvie, Preudhomme, Claude, Castaigne, Sylvie, Renneville, Aline
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2014
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171629/
https://ncbi.nlm.nih.gov/pubmed/25026287
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים